Open Label Extension Study to Evaluate the Safety, Tolerability and Cognitive Effects of VEL015 (Sodium Selenate) in Patients with Alzheimer’s Disease

This study is an extension of an earlier Alzheimer's disease trial that tested sodium selenate, a form of selenium that may slow disease progression by targeting a specific protein in the brain called tau. This extension study gives participants who completed the original trial the chance to continue receiving the drug and to be monitored for further safety and changes in memory and thinking. You may be eligible if: - You are 55 years of age or older - You completed the previous Velacor 002 Alzheimer's trial (ACTRN12611001200976) - You are living in the community with at least 5 hours of carer contact per week - Your carer is willing to help you attend assessments and take medications correctly - Women must be post-menopausal or surgically sterile You may NOT be eligible if: - You had significant or serious side effects during the original trial - You have taken part in another clinical drug trial in the past 3 months - You have a known sensitivity to selenium or sodium selenate - You have a type of dementia other than Alzheimer's disease - You have significant kidney, liver, or blood problems - You take certain medications with narrow safe dose ranges (e.g. warfarin, carbamazepine) Talk to your doctor about whether this trial might be right for you.